Innate Pharma S.A.

Healthcare · Biotechnology · France

Last price 1.5 USD (Oct 30, 2026, 9:37 AM EDT) · Market cap 134.53M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant...